Deep Subgluteal Block vs PENG Combined With LFCN Block for Analgesia After Hip Arthroplasty

ConditionPostoperative Pain

Trial statusRecruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age18-80

SponsorMedipol University

About this trial

This randomized, prospective study aims to compare the clinical efficacy of ultrasound-guided Deep Subgluteal Block (DSGB) versus Pericapsular Nerve Group (PENG) block combined with Lateral Femoral Cutaneous Nerve (LFCN) block for postoperative analgesia management in patients undergoing hip arthroplasty.

A total of 60 patients scheduled for hip arthroplasty under general anesthesia will be randomly allocated into two equal groups of 30: Group DSG and Group PENG+LFCN. Total local anesthetic volume (30 mL) and active drug dose (75 mg bupivacaine) will be standardized across both groups to ensure rigorous blinding and high methodological quality.

The primary outcome of the study is to compare total postoperative opioid (fentanyl) consumption within the first 24 hours. Secondary outcomes include postoperative pain scores evaluated via the Numerical Rating Scale (NRS) at rest and during movement, the presence and degree of quadriceps motor block, and opioid-related adverse effects (e.g., nausea, vomiting, pruritus).

Eligibility criteria

Qualifiers

Patients scheduled for elective total or partial hip arthroplasty under general anesthesia

American Society of Anesthesiologists (ASA) physical status I-III

Aged between 18 and 80 years

Able to understand the study procedures, give voluntary written informed consent, and operate a patient-controlled analgesia (PCA) device

Disqualifiers

Patient refusal or inability to provide informed consent

Pre-existing peripheral neuropathy, cognitive impairment, or psychiatric disorders

History of significant severe renal or hepatic failure

Allergy or hypersensitivity to amide-type local anesthetics or opioids

Trial design

Treatments tested in this trial

0.25% Bupivacaine for Deep Subgluteal Block
0.25% and 0.125% Bupivacaine for PENG+LFCN Block

Treatment groups

60 Participants

are divided into 2 treatment groups

Sponsors and collaborators

Medipol University

Lead sponsor

Source ClinicalTrials.gov